BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 31023030)

  • 21. Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients.
    Sasidharan Nair V; Saleh R; Toor SM; Alajez NM; Elkord E
    Front Oncol; 2020; 10():1530. PubMed ID: 32984004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD205
    Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
    Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 24. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
    Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
    Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
    Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
    Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating CD15
    Tian X; Wang T; Zheng Q; Tao Y; Dai L; Shen H
    Int J Clin Pract; 2021 Aug; 75(8):e14317. PubMed ID: 33960078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
    Sheng IY; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan TD; Rini BI; Garcia JA; Grivas P; Ornstein MC
    Target Oncol; 2020 Apr; 15(2):211-220. PubMed ID: 32207064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy.
    Foureau DM; Guo F; Steuerwald NM; Druhan LJ; Avalos BR; Copelan E; Sun D; Hu B; Moyo T; Jacobs R; Park S; Ghosh N
    Exp Hematol; 2024 Jan; 129():104125. PubMed ID: 38743005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
    Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
    Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Changed percentage of myeloid-derived suppressor cells in the peripheral blood of prostate cancer patients and its clinical implication].
    Zhou QZ; Liu CD; Yang JK; Guo WB; Zhou JH; Bian J
    Zhonghua Nan Ke Xue; 2016 Nov; 22(11):963-967. PubMed ID: 29281201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The roles of polymorphonuclear myeloid-derived suppressor cells in endometriosis.
    Satake E; Koga K; Takamura M; Izumi G; Elsherbini M; Taguchi A; Makabe T; Takeuchi A; Harada M; Hirata T; Hirota Y; Wada-Hiraike O; Osuga Y
    J Reprod Immunol; 2021 Nov; 148():103371. PubMed ID: 34517223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis.
    Uhel F; Azzaoui I; Grégoire M; Pangault C; Dulong J; Tadié JM; Gacouin A; Camus C; Cynober L; Fest T; Le Tulzo Y; Roussel M; Tarte K
    Am J Respir Crit Care Med; 2017 Aug; 196(3):315-327. PubMed ID: 28146645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD14
    Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
    Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
    J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.
    Sun HL; Zhou X; Xue YF; Wang K; Shen YF; Mao JJ; Guo HF; Miao ZN
    World J Gastroenterol; 2012 Jul; 18(25):3303-9. PubMed ID: 22783056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of myeloid-derived suppressor cells with C-reactive protein, ferritin and lactate dehydrogenase levels in patients with severe COVID-19.
    Emsen A; Sumer S; Tulek B; Cizmecioglu H; Vatansev H; Goktepe MH; Kanat F; Koksal Y; Arslan U; Artac H
    Scand J Immunol; 2022 Jan; 95(1):e13108. PubMed ID: 34625989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.